Relay Therapeutics, Inc.
399 Binney Street
2nd Floor
Cambridge, MA 02139
United States
617 370 8837
https://www.relaytx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 323
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Alexis A. Borisy A.M. | Co-Founder & Independent Chairman | 85k | 無 | 1972 |
| Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS | CEO, President & Director | 1.03M | 4.48M | 1974 |
| Dr. Mark Murcko Ph.D. | Co-Founder & Director | 50k | 無 | 1960 |
| Mr. Thomas Catinazzo | Chief Financial Officer | 599.83k | 1.02M | 1977 |
| Mr. Brian R. Adams J.D. | Chief Legal Officer & Secretary | 598.53k | 無 | 1974 |
| Dr. Donald A. Bergstrom M.D., Ph.D. | President of Research & Development | 711.25k | 3.39M | 1972 |
| Mr. Peter Rahmer | Chief Corporate Development Officer | 570.52k | 519.96k | 無 |
| Dr. Deborah Palestrant M.B.A., Ph.D. | Vice President of Corporate Development & Strategy | 無 | 無 | 無 |
| Mr. Jim Watters Ph.D. | Chief Scientific Officer of Late Research | 無 | 無 | 無 |
| Dr. Beni B. Wolf M.D., Ph.D. | Chief Medical Officer & Head of Precision Medicine | 無 | 無 | 無 |
描述
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
公司管治
截至 2024年4月1日 止，Relay Therapeutics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：5；董事會：7；股東權利：8；現金賠償：8。
